Study of Lopinivar and HCQ plasma concentrations and CRP levels in late stage (treatment initiation median 8 days from onset) COVID-19 patients. The median HCQ plasma concentration was 171 ng/ml, which authors suggest indicates that HCQ levels achieved
in vivo do not result in adequate clinical activity for COVID-19, however this is incorrect as tissue concentration can be many times higher [1].
Marzolini et al., 7/8/2020, peer-reviewed, 18 authors.